Leukemia Therapeutics Market Development And Business Intelligence

Summary

• Major factors influencing the growth of the market.
• Leading players & Top Segments.
• Geographic Overview.

Market growth influenced due to following factors-

• Growing geriatric population.

• Introduction of innovative therapies for the treatment of leukemia.

• Tissue engineering, new drugs & therapies launches.

Global market size-

According to the new market research report the leukemia therapeutics market is projected to reach $17.1 billion by 2024, at a CAGR of 6.8% during the forecast period. 

Leading Players-

The major players in the leukemia therapeutics market are Sanofi (France), AbbVie (US), Bristol-Myers Squibb (US), Novartis (Switzerland), F. Hoffmann-La Roche (Switzerland), Pfizer (US), Amgen (US), Takeda Pharmaceutical (Japan), Gilead Sciences (US), and Celgene (US). Product launches and acquisitions are the key growth strategies adopted by most players in this market. 

Top Market Segments-

Based on treatment type, the leukemia therapeutics market is bifurcated into chemotherapy and targeted drugs & immunotherapy. Of these, the targeted drugs & immunotherapy segment accounted for the largest market share in 2018.

Based on the type of leukemia, the leukemia therapeutics market is segmented into acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML). Of these, the chronic myeloid leukemia segment accounted for the largest market share in 2018. It is also anticipated to register the highest growth during the forecast period.

For Details, Download PDF Brochure

Geographic Overview -

The North American market is expected to account for the largest share, globally. The rising number of leukemia patients, tissue engineering, new drugs & therapies launches, and high research funding for the treatment of leukemia are the major driving factors in this market. In 2018, according to the Leukemia & Lymphoma Society, an estimated 381,774 people were living with or in remission from leukemia in the US. According to the Canadian Cancer Society, nearly 138,100 people in Canada are living with or are in remission from blood cancer (data as of 2016). In addition, nearly 22,340 Canadians of all ages were diagnosed with a form of blood cancer, including 5,900 cases of leukemia.